Stay informed with the latest litigation news. Explore now

Array Biopharma competitive analysis

Latest publications and patents of Array Biopharma New

Explore the latest publications and patents granted to Array Biopharma, showcasing their recent innovations and technological advancements.

Last updated on: Sep 12, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Array Biopharma

Nov 22, 2023Formulation Comprising A Mek InhibitorGranted And Under Opposition
Nov 2, 2022Pharmaceutical CombinationsRevoked
Dec 2, 2020Compounds For Use In The Treatment Of Erbb2+ Brain CancerGranted And Under Opposition
Jan 31, 2018Serine/Threonine Kinase InhibitorsNo Opposition Filed Within Time Limit
Jan 31, 2018Serine/Threonine Kinase InhibitorsNo Opposition Filed Within Time Limit
Jan 10, 2018N-Pyrrolidinyl, N'-Pyrazolyl- Urea, Thiourea, Guanidine And Cyanoguanidine Compounds As Trka Kinase InhibitorsNo Opposition Filed Within Time Limit
Jul 19, 2017N3 Alkylated Benzimidazole Derivative As Mek InhibitorRevoked

Explore Array Biopharma's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 18, 2025
Patent NumberGrant DateTitleTotal Oppositions
Nov 22, 2023Formulation Comprising A Mek Inhibitor2
Nov 2, 2022Pharmaceutical Combinations2
Dec 2, 2020Compounds For Use In The Treatment Of Erbb2+ Brain Cancer2
Jul 19, 2017N3 Alkylated Benzimidazole Derivative As Mek Inhibitor1

Latest PTAB cases involving Array Biopharma New

Discover the latest PTAB cases involving Array Biopharma, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 18, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Array Biopharma

IPR2015-00754Feb 17, 2015ARRAY BIOPHARMATAKEDA PHARMACEUTICALFinal Written Decision

Top competitors of Array Biopharma

Top competitors of Array Biopharma based on patent oppositions.